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Abstract
Mucosal bleeding is a well-known 
complication of having a ventricular assist 
device and commonly presents with epistaxis. 
Although the frequency of epistaxis as a 
complication in patients with a ventricular 
assist device has been documented in the 
literature, to our knowledge the cost of this 
complication has not been reported. This 
case report examines the financial burden 
of ventricular assist device-associated 
epistaxis in a single patient from September 
2018 to December 2019 using ICD 10 
diagnostic codes. The patient was found 
to have accumulated $138,020 in costs 
over 38 encounters. This case report not 
only highlights the recurrent nature and 
potential high cost of epistaxis in this patient 
population, but also identifies a target to 
reduce healthcare spending. Further research 
is needed to assess whether cheap and simple 
preventative measures such as nasal hygiene 
regimen can decrease the frequency and/
or severity of epistaxis in the patients with a 
ventricular assist device.
Introduction
Epistaxis is a well-documented complication 
of having a ventricular assistive device 
(VAD). Multiple factors, including dual 
anticoagulation/antiplatelet therapy and 
acquired clotting deficiencies contribute to 
mucosal bleeding.1 Studies have demonstrated 
that the most common presenting complaint 
to the emergency department in a patient 
with a VAD is mucosal bleedingg.2 While 
most otolaryngologists are aware of the 
frequency of epistaxis in this population, to 
our knowledge the cost of this complication 
has not been reported. In this case report, 
we document financial costs of epistaxis in a 
patient with a VAD over a 16-month period. 
Case Presentation
A patient with a known history of mucosal 
bleeding was studied to examine the financial 
burdens of VAD-associated epistaxis. Using 
ICD codes, VAD-associated encounters were 
extracted from the patient’s medical records 
over a 16-month period. The financial costs 
for each of these inpatient and outpatient 
encounters were obtained. Only the 
encounters associated with ICD 10 diagnosis 
of epistaxis or respiratory hemorrhage were 
included in the final analysis. Information 
regarding encounter type was extracted from 
the patient’s medical record. All information 
extracted from this patient’s medical records 
is in accordance with privacy standards set 
by Nebraska Medicine and the University of 
Nebraska Medical Center. 
Analysis of clinic visits, emergency 
department visits, and inpatient management 
for this patient with a VAD revealed 38 total 
encounters to treat recurrent episodes of 
epistaxis. Of the 38 total encounters, fifteen 
of them were clinic visits resulting in $5,890 
in total costs. The patient was evaluated in 
the emergency department and subsequently 
discharged on nine occasions tallying $10,449 
in total costs. The patient was admitted in 
an inpatient setting 14 times over the course 
of the selected time period. These inpatient 
hospitalizations accrued $121,682 in costs. 
Overall, the average total cost per inpatient 
hospitalization for epistaxis was $8,692. 
Emergency department encounters averaged 
nearly $1200 per visit. The mean total cost of 
each clinic encounter was $393 (Figure 1 and 
Table 1).
Discussion
To our knowledge, this is the first report to 
outline the costs associated with epistaxis 
in patients with VADs. The studied patient 
presented to a tertiary care center 38 times 
over the course of a 16-month period for 
management of epistaxis. Over half of the 
encounters were in the emergency department 
(61%), and the patient was admitted for 
inpatient management of epistaxis 14 times. 
The patient was evaluated 15 times in the 
clinic setting for management and follow-
up of epistaxis. Unsurprisingly, inpatient 
hospitalization comprised the vast majority of 
total costs over the selected time period. The 
differences in costs between levels of care are 
expected, however, the number of encounters 
outside of a clinic setting shed light on the 
Table 1. 
Number of Encounters Cumulative Cost Total cost/encounter
Clinic 15 $5,890 $393
Emergency Department 9 $10,449 $1,161
Inpatient 14 $121,682 $8,692
Total 38 $138,0202 $3,632








Figure 1. Proportion of encounter types and total costs associated with encounter types. (A) 
Proportions of each encounter type. Thirty-nine percent of all encounters over the 16-month period 
were in the clinic setting. Inpatient hospitalizations accounted for 37% of all encounters, whereas 24% 
of encounters were in the emergency department. (B) Proportion of total costs by encounter type. 
Inpatient hospitalizations accounted for 88% of the total costs. Emergency department and clinic 
encounters made up 8% and 4%, respectively, of total costs accrued over the 16-month period. 
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need for prevention of epistaxis in this patient 
population. 
Previous studies have acknowledged the 
risk factors for VAD-associated epistaxis.1,3 
Patients with VADs are placed on dual 
anticoagulation and antiplatelet therapy as 
their device acts as a nidus for thrombus 
formation. These medications are vital 
for the prevention of ventricular device 
failure secondary to pump thrombosis. 
Furthermore, the presence of the VAD 
leads to the mechanical destruction of von 
Willebrand factor, predisposing patients to 
bleeding dyscrasias. Healthcare providers 
are tasked with balancing the pro-coagulant 
effects of VAD with the complications of 
anticoagulation therapy. 
The management of epistaxis in patients with 
VAD can be aimed at prevention of epistaxis 
occurrence or the acute intervention of an 
actively bleeding nose. In 2018, Brown et al. 
reviewed the various management options 
for acute intervention in patients with VAD-
associated epistaxis. Most notably, they 
found that the use of hemostatic agents, both 
dissolvable and non-dissolvable resulted in 
a lower likelihood of bleeding recurrence in 
comparison to those treated with silver nitrate 
cauterization.3 Despite conservative measures 
with nasal packing, vasoactive substances, 
and hemostatic agents, massive hemorrhage 
can ensue and become life-threatening, 
ultimately requiring surgical management. 
While endoscopic surgical ligation of the 
sphenopalatine artery is a commonly used 
approach, endovascular embolization 
procedures have been demonstrated to be 
similarly effective while being minimally 
invasive.4 
This case report highlights the importance 
of epistaxis prevention in patients with 
VADs. While nasal packing and vasoactive 
substances are useful in the management 
of acute bleeding, they do not prevent 
recurrence of bleeding. Similarly, hemostatic 
agents provide elements of short-term 
epistaxis prevention until they are removed 
or dissolved. The mainstay of epistaxis 
prevention in anticoagulated patients is the 
use of moisturizing agents, such as nasal 
saline gels and Vaseline. Although no control 
group was used for comparison, Massick et 
al. found that 93% of anticoagulated patients 
experienced cessation of their epistaxis at 
three months with use of nasal saline gel.5,6 
Despite these findings, no research has 
been dedicated to evaluating the prevention 
of epistaxis in patients with VAD. Nasal 
hygiene measures are simple to use and 
cheap for patients in preventing epistaxis. 
Although this case report does not delve into 
the specific interventions utilized at each 
encounter, it calls attention to the importance 
of preventative care in reducing healthcare 
burden and total healthcare costs. 
Conclusion
The financial burden of epistaxis in 
anticoagulated patients can be astounding. 
This case report reviews the types of 
encounters and total costs associated with 
epistaxis in a patient with a VAD over a 
16-month period. This case report identifies 
a potential target to reduce healthcare 
expenditures through the use of cheap and 
simple preventative nasal hygiene measures. 
Further research should be dedicated to 
elucidating the most effective options for 
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